Effectiveness of Rotarix™ Against Rotavirus Severe Gastroenteritis (RV SGE) in Infants in Panama
Completed
- Conditions
- Infections, Rotavirus
- Interventions
- Other: No intervention
- Registration Number
- NCT00653198
- Lead Sponsor
- GlaxoSmithKline
- Brief Summary
This study aims to estimate the effectiveness of Rotarix™ vaccine which is used nationwide as a part of the expanded program on immunization (EPI), in preventing RV SGE among hospitalised children born after 1 March 2006, which corresponds to the date of introduction of Rotarix™ in the national immunization program.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 885
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description B No intervention Controls A No intervention Cases
- Primary Outcome Measures
Name Time Method Occurrence of RV GE among children born after 1 March 2006, at least 12 weeks of age and admitted to the study hospital for SGE.
- Secondary Outcome Measures
Name Time Method Occurrence of acute GE among children born after 1 March 2006, at least 12 weeks of age and admitted to the study hospital for SGE.
Trial Locations
- Locations (1)
GSK Investigational Site
🇵🇦Panama, Panama